Alnylam Pharmaceuticals, Inc. balance sheet
At the end of its fiscal year on Dec 31, 2025, Alnylam Pharmaceuticals, Inc. reported total assets of $4.97B and shareholders' equity of $789.18M. That works out to liabilities equal to 84% of assets, a current ratio of 2.76 (current assets ÷ current liabilities).
Balance sheet at each fiscal year end
| Fiscal year ended | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.26B | $1.99B | $1.57B | $2.40B | $3.41B | $3.64B | $3.55B | $3.83B | $4.24B | $4.97B |
| Current assets | $671.88M | $1.76B | $1.20B | $1.72B | $2.61B | $2.81B | $2.69B | $2.98B | $3.30B | $4.05B |
| Cash & equivalents | $193.62M | $645.36M | $420.15M | $547.18M | $496.58M | $819.98M | $866.39M | $812.69M | $966.43M | $1.66B |
| Total liabilities | $342.59M | $228.30M | $272.84M | $956.44M | $2.39B | $3.06B | $3.70B | $4.05B | $4.17B | $4.18B |
| Current liabilities | $131.70M | $144.25M | $179.49M | $352.59M | $585.27M | $695.71M | $767.91M | $967.79M | $1.19B | $1.47B |
| Shareholders' equity | $920.22M | $1.77B | $1.30B | $1.44B | $1.02B | $588.20M | −$158.22M | −$220.64M | $67.09M | $789.18M |
| Reported in | 10-K 2018 | 10-K 2019 | 10-K 2020 | 10-K 2021 | 10-K 2022 | 10-K 2023 | 10-K 2024 | 10-K 2025 | 10-K 2026 | 10-K 2026 |
Balance-sheet figures are point-in-time values on the last day of each fiscal year. Some companies (for example banks and insurers) do not present current assets and liabilities; those cells show —.
Source: SEC EDGAR XBRL company facts for CIK 1178670 (raw data). Most recent filing in this dataset: 10-Q filed Oct 29, 2026. SEC data file dated Nov 3, 2026; page built Nov 5, 2026. Figures are as most recently reported, including restatements. How we select figures.